An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Latest Information Update: 18 Oct 2024
Price :
$35 *
At a glance
- Drugs DSP 107 (Primary) ; Azacitidine; Azacitidine; Venetoclax
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Lymphoproliferative disorders; Myelodysplastic syndromes; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors KAHR Medical
- 14 Oct 2024 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 14 Oct 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Jun 2025.
- 09 Mar 2023 Planned End Date changed from 1 Apr 2023 to 1 Dec 2024.